Cancer Connected Access and Remote Expertise (CARE) Beyond Walls Program
This study, called the Cancer Connected Access and Remote Expertise (CARE) Beyond Walls (CCBW) program, is looking at whether receiving your standard cancer treatment at home is preferred over going to a clinic. It also wants to see if home treatment makes patients more satisfied. You might be able to join if you are an adult cancer patient in the Florida Panhandle or surrounding areas, are receiving a standard cancer treatment, and your doctor believes you can tolerate it well. The study aims to understand patient preferences for treatment location and track any side effects related to where you receive treatment. We are also looking at how many urgent care, emergency room, or hospital visits happen. The study plans to enroll 27 participants.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment or procedure. It plans to enroll 27 participants.
- What's involved
- Participants will either receive their standard of care cancer treatment at home or in the clinic. They will also complete questionnaires.
- Compensation
- Not stated in the trial record.
- Follow-up
- Patient preferences will be measured at 12 weeks. Adverse events will be tracked for up to 9 months, and acute care visits for up to 24 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Roxana S. Dronca, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Patient preferences regarding location of cancer treatment deliveryAt 12 weeks
As assessed by a single item asking patients to rate their preferred location for cancer treatment delivery on a 1 to 7 scale: 1 = strongly prefer in clinic, 2 = moderately prefer in clinic, 3 = slightly prefer in clinic, 4 = no preference, 5 = slightly prefer at home, 6 = moderately prefer at home, 7 = strongly prefer at home. Patients who receive any care in the mobile unit will be instructed to consider "at home" to mean receipt of care inside their home or near their home in the mobile unit.
- Adverse Events Related to Location of TreatmentUp to 9 months
Safety of at-home administration of cancer treatment will be assessed by incidence of grade 3+ adverse events at least possibly related to the location of cancer treatment delivery that occur up to 30 days after the administration of the last dose of study drug/agent or therapy. The maximum grade for each type of adverse event will be summarized using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
- Incidence of avoidable acute care visits, emergency room visits, and hospitalizationsUp to 24 weeks
Safety of at-home administration of cancer treatment will be assessed by the frequency and proportion of patients who experience an avoidable (in the opinion of the treating physician) acute care visit, emergency room visit, or hospitalization while receiving at-home cancer treatment.